Objective  To explore the application of an innovative quality control circle (QCC) based on quality function deployment (QFD) in constructing a comprehensive pharmaceutical management model for chemotherapy-induced nausea and vomiting (CINV) in cancer patients.

Methods  A QCC team was established, the KANO model, a demand classification tool, was used to analyze the needs of patients following the eight steps of QFD, to clarify the nature of different demands, and determine their weights. Based on QFD theory, the needs of patients were transformed into measurable quality characteristics, and their importance was calculated. A bottleneck analysis was conducted by integrating importance scores with difficulty values. Finally, innovative action plans were proposed and implemented based on key quality characteristics.

Results  Sixteen needs were collected and identified, and priority analysis highlighted two key issues: reducing the rate of inappropriate medication use and improving satisfaction with pharmaceutical services. These goals were achieved through measures such as building a comprehensive information management platform for CINV medications, establishing a multidisciplinary team (MDT) teaching alliance comprising doctors, pharmacists, and nurses, and optimizing oncology pharmaceutical services. Improvements in several components were obtained after the implementation of the activity, with an improved chemotherapy prescription failure rate of 10%, antiemetic medication irrationality rate of 25%, CINV assessment pass rate of 98%, CINV incidence rate of 65%, antiemetic medication adherence of 91%, and oncology patient satisfaction with pharmacy services of 98%.

Conclusion  This initiative adopted an innovative QCC approach based on QFD, starting from the needs of cancer patients undergoing chemotherapy. It addressed existing issues in pharmaceutical services and successfully constructed a comprehensive pharmaceutical management model for patients with CINV.

1.Razvi Y, Chan S, McFarlane T, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients[J]. Support Care Cancer, 2019, 27(1): 87-95. DOI: 10.1007/s00520-018-4464-y.

2.Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends[J]. Cancer Treat Res Commun, 2021, 26: 100278. DOI: 10.1016/j.ctarc.2020.100278.

3.Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer[J]. Support Care Cancer, 2005, 13(4): 219-227. DOI: 10.1007/s00520-004-0710-6.

4.Haiderali A, Menditto L, Good M, et al. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population[J]. Support Care Cancer, 2011, 19(6): 843-851. DOI: 10.1007/s00520-010-0915-9.

5.Woopen H, Richter R, Chekerov R, et al. Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data Meta-analysis in 1213[J]. Support Care Cancer, 2020, 28(1): 73-78. DOI: 10.1007/s00520-019-04778-1.

6.Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.

7.Yu J, Zhang Z, Zhou H, et al. The perception gap of chemotherapy-induced adverse events between doctors and cancer patients: an observational study in China[J]. Support Care Cancer, 2021, 29(3): 1543-1548. DOI: 10.1007/s00520-020-05649-w.

8.Hsieh RK, Chan A, Kim H, et al. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries[J]. Support Care Cancer, 2015, 23(1): 263-272. DOI: 10.1007/s00520-014-2373-2.

9.Keefe DMK, Chan A, Kim H, et al. Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study[J]. Support Care Cancer, 2015, 23(1): 253-261. DOI: 10.1007/s00520-014-2374-1.

10.Herrstedt K, Lindberg S, Petersen PC. Prevention of chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes[J]. Drugs Aging, 2022, 39(1): 1-21. DOI: 10.1007/s40266-021-00909-8.

11.中国药学会医院药学专业委员会. 化疗所致恶心呕吐的药物防治指南[J]. 中国医院药学杂志, 2022, 42(5): 457-473. [Hospital Pharmacy Committee of Chinese Pharmaceutical Association. Guideline for drug prevention and treatment of chemotherapy-induced nausea and vomiting[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(5): 457-473.] DOI: 10.13286/j.1001-5213.2022.05.01.

12.Kennedy SKF, Goodall S, Lee SF, et al. 2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients[J]. Support Care Cancer, 2024, 32(5): 280. DOI: 10.1007/s00520-024-08462-x.

13.《四川省防控抗肿瘤药物治疗相关恶心呕吐专家共识》编写专家组. 四川省防控抗肿瘤药物治疗相关恶心呕吐专家共识2024版[J]. 中国循证医学杂志, 2024, 24(10): 1129-1136. [Sichuan Province Anti Cancer Drug Induced Nausea and Vomiting Experts Consensus Compilation Expert Group. Expert consensus on the prevention and treatment of anti cancer drug induced nauseaand vomiting of Sichuan province (2024)[J]. Chinese Journal of Evidence-Based Medicine, 2024, 24(10): 1129-1136.] DOI: 10.7507/1672-2531.202407066.

14.上海市抗癌协会癌症康复与姑息治疗专业委员会. 抗肿瘤治疗所致恶心呕吐全程管理上海专家共识（2024年版）[J]. 中国癌症杂志, 2024, 34(1): 104-134. [Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association. Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)[J]. China Oncology, 2024, 34(1): 104-134.] DOI: 10.19401/j.cnki.1007-3639.2024.01.008.

15.Aapro M, Caprariu Z, Chilingirov P, et al. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: results of the nausea/emesis registry in oncology (NERO)[J]. Eur J Cancer, 2022, 166: 126-133. DOI: 10.1016/j.ejca.2022.01.028.

16.张丹, 严越, 刘庭芳. 品管圈现况把握阶段常见问题解析 [J]. 中国医院管理, 2021, 41(3): 42-45. [Zhang D, Yan Y, Liu  TF. Analysis of main problems in the current situation control stage of quality control circle[J]. Chinese Hospital Management, 2024, 41(3): 42-45.] https://www.nstl.gov.cn/paper_detail.html?id=1e37ce320c73d383b8530676d5796ed6.

17.杨凝, 张丹, 刘庭芳. 医院品管圈对策实施与效果确认阶段常见问题解析[J]. 中国医院, 2022, 26(6): 57-60. [Yang N, Zhang D, Liu TF. Analysis of common questions in the stage of strategy implementing and effect confirmation of hospital quality control circle measures[J]. Chinese Hospitals, 2022, 26(6): 57-60.] DOI: 10.19660/j.issn.1671-0592.2022.6.18.

18.赤尾洋二. 质量功能展开方法的研究与应用（节选）——质量功能展开和知识管理[J]. 中国质量, 2008, (10): 8. [Yoji A. Application of QFD methodology in development of a new wallet-QFD and knowledge management[J]. China Quality, 2008, (10): 8.] DOI: 10.16434/j.cnki.zgzl.2008.10.015.

19.Van Laar ES, Desai JM, Jatoi A. Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers[J]. Support Care Cancer, 2015, 23(1): 151-157. DOI: 10.1007/s00520-014-2325-x.